Azacitidine

Generic Name
Azacitidine
Brand Names
Onureg, Vidaza, Azacitidine Accord, Azacitidine betapharm, Azacitidine Mylan, Azacitidine Kabi
Drug Type
Small Molecule
Chemical Formula
C8H12N4O5
CAS Number
320-67-2
Unique Ingredient Identifier
M801H13NRU
Background

Azacitidine is a pyrimidine nucleoside analogue with anti-neoplastic activity. It differs from cytosine by the presence of nitrogen in the C5-position, key in its hypomethylating activity. Two main mechanisms of action have been proposed for azacitidine. One of them is the induction of cytotoxicity. As an analogue of cytidine, it is able to incorporate into ...

Indication

Azacitidine (for subcutaneous or intravenous use) is indicated for the treatment of adult patients with the following French-American-British (FAB) myelodysplastic syndrome (MDS) subtypes: refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemi...

Associated Conditions
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Refractory Anemia, Refractory Anemia With Excess Blasts in Transformation, Refractory Anemia With Excess of Blasts (RAEB), Refractory Anemia With Ringed Sideroblasts, Newly diagnosed Juvenile Myelomonocytic Leukaemias (JMML)
Associated Therapies
-
Clinical Trials
Related News

A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

First Posted Date
2024-08-12
Last Posted Date
2024-11-25
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
40
Registration Number
NCT06548230
Locations
🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia

First Posted Date
2024-07-26
Last Posted Date
2024-10-30
Lead Sponsor
Uma Borate
Target Recruit Count
52
Registration Number
NCT06523556
Locations
🇺🇸

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML

First Posted Date
2024-07-23
Last Posted Date
2024-12-18
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
45
Registration Number
NCT06514261
Locations
🇺🇸

UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States

🇺🇸

UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States

🇺🇸

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States

Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD

First Posted Date
2024-07-22
Last Posted Date
2024-11-29
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Target Recruit Count
37
Registration Number
NCT06511882
Locations
🇺🇸

Moffitt Cancer Center, Tampa, Florida, United States

A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies

First Posted Date
2024-07-18
Last Posted Date
2024-11-29
Lead Sponsor
Sanofi
Target Recruit Count
18
Registration Number
NCT06508489
Locations
🇺🇸

City of Hope National Medical Center- Site Number : 8400003, Duarte, California, United States

🇦🇺

Investigational Site Number : 0360002, Wollongong, New South Wales, Australia

🇦🇺

Investigational Site Number : 0360001, Melbourne, Victoria, Australia

Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML

First Posted Date
2024-07-16
Last Posted Date
2024-07-16
Lead Sponsor
OHSU Knight Cancer Institute
Target Recruit Count
40
Registration Number
NCT06504459
Locations
🇺🇸

OHSU Knight Cancer Institute, Portland, Oregon, United States

Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant

First Posted Date
2024-07-12
Last Posted Date
2024-10-29
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
43
Registration Number
NCT06498973
Locations
🇺🇸

City of Hope Medical Center, Duarte, California, United States

Phase II Study of Sonrotoclax Combined With Chemotherapy in the Treatment of Newly Diagnosed Acute Myeloid Leukemia

First Posted Date
2024-07-11
Last Posted Date
2024-07-11
Lead Sponsor
Shanghai Jiao Tong University School of Medicine
Target Recruit Count
47
Registration Number
NCT06497062
Locations
🇨🇳

Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China

Fourth Ventricular Administration of Immune Checkpoint Inhibitor (Nivolumab) and Methotrexate or 5-Azacytidine for Recurrent Medulloblastoma, Ependymoma, and Other CNS Malignancies

First Posted Date
2024-06-20
Last Posted Date
2024-12-06
Lead Sponsor
David Ilan Sandberg
Target Recruit Count
10
Registration Number
NCT06466798
Locations
🇺🇸

The University of Texas Health Science Center at Houston, Houston, Texas, United States

Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation

First Posted Date
2024-06-20
Last Posted Date
2024-12-10
Lead Sponsor
Institut de Recherches Internationales Servier
Target Recruit Count
48
Registration Number
NCT06465953
Locations
🇯🇵

University of Fukui Hospital, Yoshida-gun, Eiheiji-cho 670-8540 Himeji, Japan

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy